% IMPORTANT: The following is UTF-8 encoded. This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.
@ARTICLE{Wolff:284356,
author = {Wolff, Andreas and Feneberg, Emily and Shakhtour, Julius
and Steiger, Katja and Schmid, Roland M. and Haller,
Bernhard and Reinhardt, Nya and Middelhoff, Moritz and
Schult-Hannemann, David and Lingor, Paul},
title = {{R}etrospective analysis of neurofilament-light chain in
patients with inflammatory bowel disease – {A} pilot
study},
journal = {PLOS ONE},
volume = {21},
number = {1},
issn = {1932-6203},
address = {San Francisco, California, US},
publisher = {PLOS},
reportid = {DZNE-2026-00124},
pages = {e0340182},
year = {2026},
abstract = {Chronic inflammatory bowel diseases, encompassing Crohn's
disease and ulcerative colitis, are characterized by
persistent inflammation of the gastrointestinal tract. While
traditionally regarded as confined to the gut, the systemic
nature of inflammatory bowel disease has been increasingly
recognized. The nervous system has garnered particular
attention due to molecular and clinical evidence suggesting
a potential interplay between inflammatory bowel disease and
neurodegenerative diseases. Inflammatory bowel disease
patients have a higher risk of developing neurological
disorders such as Parkinson's disease, all-cause dementia,
and multiple sclerosis. Still, causative molecular
mechanisms are poorly understood. Neurofilament light chain
(NfL) has been established as a disease-independent
biomarker of axonal damage reflecting neurodegeneration.In
this pilot study, we assessed molecular evidence of
neurodegeneration by measuring serum NfL in a
single-molecule array using the HD-X SIMOA platform
(Quanterix, MA, USA) and employing correlation with clinical
data in forty-nine patients with histopathologically
confirmed inflammatory bowel disease. In total, 24 Crohn's
disease patients, 25 ulcerative colitis patients, and 23
controls, aged 18-79 years, were included.We found an
age-dependency of serological NfL levels, however, no
apparent differences between disease groups and controls.
Crohn's disease patients showed a slower age-dependent
incline in serological NfL compared to control subjects (p =
0.03). No correlation of NfL with disease duration, disease
severity, or inflammatory bowel disease treatment was
found.A slower age-dependent increase in serological NfL
levels was found in Crohn's disease patients compared to
control subjects. Larger studies assessing additional
markers of neurodegeneration may be instrumental in
addressing this question in the future.},
keywords = {Humans / Neurofilament Proteins: blood / Pilot Projects /
Adult / Middle Aged / Male / Female / Aged / Biomarkers:
blood / Adolescent / Young Adult / Retrospective Studies /
Inflammatory Bowel Diseases: blood / Crohn Disease: blood /
Crohn Disease: pathology / Colitis, Ulcerative: blood /
Colitis, Ulcerative: pathology / Case-Control Studies /
Neurofilament Proteins (NLM Chemicals) / neurofilament
protein L (NLM Chemicals) / Biomarkers (NLM Chemicals)},
cin = {Clinical Research (Munich)},
ddc = {610},
cid = {I:(DE-2719)1111015},
pnm = {353 - Clinical and Health Care Research (POF4-353)},
pid = {G:(DE-HGF)POF4-353},
typ = {PUB:(DE-HGF)16},
doi = {10.1371/journal.pone.0340182},
url = {https://pub.dzne.de/record/284356},
}